Effect of thalidomide and immunomodulatory drugs on T cells in healthy donors and patients with multiple myeloma
| . | Stimulation index of CD3+ cells . | P . | |
|---|---|---|---|
| Healthy donors . | Myeloma patients . | ||
| Thal | Mean, 4.1 | Mean, 2.2 | .12 |
| Range, 2.3-5.9 | Range, 1.5-3.1 | ||
| IMiD1 | Mean, 3.7 | Mean, 4.1 | .8 |
| Range, 1.3-5.4 | Range, 1.9-6.1 | ||
| IMiD2 | Mean, 5.2 | Mean, 7.2 | .4 |
| Range, 2.6-7.3 | Range, 2.5-11.3 | ||
| IMiD3 | Mean, 3.2 | Mean, 3.3 | .92 |
| Range, 1.3-5.4 | Range, 2.1-5.3 | ||
| . | Stimulation index of CD3+ cells . | P . | |
|---|---|---|---|
| Healthy donors . | Myeloma patients . | ||
| Thal | Mean, 4.1 | Mean, 2.2 | .12 |
| Range, 2.3-5.9 | Range, 1.5-3.1 | ||
| IMiD1 | Mean, 3.7 | Mean, 4.1 | .8 |
| Range, 1.3-5.4 | Range, 1.9-6.1 | ||
| IMiD2 | Mean, 5.2 | Mean, 7.2 | .4 |
| Range, 2.6-7.3 | Range, 2.5-11.3 | ||
| IMiD3 | Mean, 3.2 | Mean, 3.3 | .92 |
| Range, 1.3-5.4 | Range, 2.1-5.3 | ||
Thal indicates thalidomide; IMiD, immunomodulatory drugs.
CD3+ cells from 4 healthy donors and 4 patients with MM were stimulated with anti-CD3 and treated with Thal/IMiDs daily (5 μg/mL) for 5 days.